Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.

Mimura, Kaito; Shimomura, Akihiko; Gota, Tomoko; Ando, Kenju; Kawamura, Yukino; Taniyama, Tomoko; Oishi, Hajime; Shimizu, Chikako

Mimura, Kaito; Shimomura, Akihiko; Gota, Tomoko; Ando, Kenju; Kawamura, Yukino; Taniyama, Tomoko; Oishi, Hajime; Shimizu, Chikako.

Afiliação

Mimura K; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Shimomura A; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Gota T; Department of Gynecology and Obstetrics, National Center for Global Health and Medicine, Tokyo, Japan.
Ando K; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Kawamura Y; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Taniyama T; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Oishi H; Department of Gynecology and Obstetrics, National Center for Global Health and Medicine, Tokyo, Japan.
Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.

Gynecol Oncol Rep ; 44: 101084, 2022 Dec.

Article em En | MEDLINE | ID: mdl-36277029

Palavras-chave

CT, computed tomography; Combination therapy; ICI, immune checkpoint inhibitor; IFN, interferon; Immune checkpoint inhibitor; Immunotherapy; MMR, mismatch repair; MSI, microsatelite instability; PD-1, programmed death-1; Tumor microenvironment; Tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Gynecol Oncol Rep Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google